Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
CT:VQ's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for CT:VQ. Showing past 6 months and next 12 months · 2 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| CT:VQ | 4DMedical | Diagnostic Device | Phase 2 | 0 | ||||
| Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging | Anna Raciborska | — | Phase 3 |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Depemokimab Asthma Imaging and Bronchoscopy Sub-Study | GlaxoSmithKline | — | Phase 3 | — | — | — | — | — |
| Imaging Immune Activation in COVID-19 | CellSight Technologies, Inc. | — | Phase 2 | — | — | — | — | — |
| Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients | Universitair Ziekenhuis Brussel | — | Phase 2 | — | — | — | — | — |
| Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors | Man Hu | — | PHASE1/PHASE2 | — | — | — | — | — |
| PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 | Memorial Sloan Kettering Cancer Center | — | PHASE1/PHASE2 | — | — | — | — | — |
| Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET) | University of Saskatchewan | — | PHASE1/PHASE2 | — | — | — | — | — |
| Synapse 3D With Intravascular Indocyanine Green | St. Joseph's Healthcare Hamilton | — | PHASE1/PHASE2 | — | — | — | — | — |
| 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer | Peking University First Hospital | — | PHASE1/PHASE2 | — | — | — | — | — |
| Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH | University Hospital, Brest | — | PHASE1/PHASE2 | — | — | — | — | — |
| Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases | Peking Union Medical College Hospital | — | PHASE1/PHASE2 | — | — | — | — | — |